PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer

참고문헌 (36)

1. Kuroki, L., "Treatment of epithelial ovarian cancer", BMJ, 371, pp.m3773~ (2020)
2. Della Corte, L., "Poly(ADPribose)polymerase(PARP)as target for the treatment of epithelial ovarian cancer : what to know", Expert Opin. Investig. Drugs, 30, pp.543~554 (2021)
3. Vanacker, H., "PARP-inhibitors in epithelial ovarian cancer : Actual positioning and future expectations", Cancer Treat. Rev, 99, pp.102255~ (2021)
4. Goel, N., "Strategies in overcoming homologous recombination proficiency and PARP inhibitor resistance", Mol. Cancer Ther, 20, pp.1542~1549 (2021)
5. Gaudet, S., "Characterization of PDZ-binding kinase, a mitotic kinase", Proc. Natl Acad. Sci. USA, 97, pp.5167~5172 (2000)
6. Abe, Y., "Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells", J. Biol. Chem, 275, pp.21525~21531 (2000)
7. Chen, D., "LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase", Neoplasia, 22, pp.231~241 (2020)
8. Yang, Q. X., "PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway", Cancer Lett, 452, pp.90~102 (2019)
9. Warren, A. Y., "A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer", Oncogene, 38, pp.1136~1150 (2019)
10. Hinzman, C. P., "Aberrant expression of PDZ-binding kinase", T-LAK celloriginated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC, 2018, pp.39, 1548~1559
11. Ohashi, T., "Overexpression of PBK", TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma, 2017, pp.116, 218~226
12. Ziping Han, "PBK", TOPK: A Therapeutic Target Worthy of Attention, 2021, pp.10(2), 371~[DOI]
13. Park, J. H., "PBK attenuates paclitaxelinduced autophagic cell death by suppressing p53 in H460 non-small-cell lung cancer cells", FEBS Open Biol, 10, pp.937~950 (2020)
14. Xiao, J., "Targeting the COX2", MET, Cell Death Dis, pp.2019, 10[DOI]
15. Cao, H., "PBK", TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTEN, 2021, pp.53, 584~592
16. Hu, F., "PBK", TOPK interacts with the DBD domain of tumor suppressor p53and modulates expression of transcriptional targets including p21, 2010, pp.29, 5464~5474
17. Ma, H., "PBK promotes aggressive phenotypes of cervical cancer through ERK", c-Myc signaling pathway, 2021, pp.236, 2767~2781
18. Ma, H., "PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma", Cell Death Dis, 10, pp.166~ (2019)
19. Fu, T., "ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NFkappaB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer", Gastric Cancer, 24, pp.45~59 (2021)
20. Wu, G., "An ATM", TRIM37, Cancer Res, pp.2018, 78[DOI]
21. Onstad, M., "Movement of Poly-ADP Ribose(PARP)inhibition into frontline treatment of ovarian cancer", Drugs, 80, pp.1525~1535 (2020)
22. Curtin, N. J., "Poly(ADP-ribose) polymerase inhibition: past, present and future", Nat. Rev. Drug Discov, 19, pp.711~736 (2020)
23. Li, H., "PARP inhibitor resistance: the underlying mechanisms and clinical implications", Mol. Cancer, 19, pp.107~ (2020)
24. Lu, H., "TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ", Cell Death Dis, 10, pp.583~ (2019)
25. Herbert, K. J., "Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress", Cell Death Differ, 28, pp.1333~1346 (2021)
26. Wu, Z. H., "Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli", Science, 311, pp.1141~1146 (2006)
27. Miyamoto, S., "Nuclear initiated NF-kappaB signaling : NEMO and ATM take center stage", Cell Res, 21, pp.116~130 (2011)
28. Huang, K., "Genome-wide CRISPR-Cas9 screening identifies NF-kappaB", E2F6responsible for EGFRvIII-associated temozolomide resistance in glioblastoma, 2019, pp.6, 1900782~
29. Bentires-Alj, M., "NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells", Oncogene, 22, pp.90~97 (2003)
30. Tan, S. F., "Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-kappaB-dependent P-glycoprotein upregulation", J. Lipid Res, 60, pp.1078~1086 (2019)
31. Medova, M., "MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks", Int J. Cancer, 130, pp.728~734 (2012)
32. Du, Y., "Blocking c-Met-mediated PARP1 phosphorylation enhances antitumor effects of PARP inhibitors", Nat. Med, 22, pp.194~201 (2016)
33. Xia, Q., "The CDK1 inhibitor RO3306 improves the response of BRCA-pro ficient breast cancer cells to PARP inhibition", Int J. Oncol, 44, pp.735~744 (2014)
34. Johnson, N., "Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition", Nat. Med, 17, pp.875~882 (2011)
35. Matulonis, U. A., "Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly(ADP ribose)polymerase(PARP)inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer", Ann. Oncol, 28, pp.512~518 (2017)
36. Konstantinopoulos, P. A., "Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer : a dose-escalation and dose-expansion phase 1b trial", Lancet Oncol, 20, pp.570~580 (2019)